IBRX261120C00011500
IBRX Nov 20 2026 11.50 Call
optionOPRA
InactiveOct 28, 2026
0.33USD+560.000%(+0.28)3Vol8OI
Loading…
Underlying
Underlying Price
$6.01
Type
Call
Strike
11.5
Expiration
Nov 20, 2026
DTE
7d
Moneyness
OTM
Intrinsic
$0.00
IBRX 11.5 Call Across Expirations
| Expiration | DTE | Last | Change | Vol | Open Int |
|---|---|---|---|---|---|
| Nov 13, 2026 | 0d | $0.65 | +22.64% | 22 | 25 |
| Nov 20, 2026 | 7d | $0.33 | +560.00% | 3 | 8 |
| Nov 27, 2026 | 14d | — | — | 0 | 0 |
| Dec 4, 2026 | 21d | — | — | 0 | 0 |
| Dec 11, 2026 | 28d | — | — | 0 | 0 |
| Dec 24, 2026 | 41d | — | — | 0 | 0 |
| Dec 31, 2026 | 48d | — | — | 0 | 0 |
IBRX Nearby Strikes · Nov 20, 2026
| Strike | Last | Change | Vol | Open Int | Moneyness |
|---|---|---|---|---|---|
| 8.5 C | $0.70 | -11.39% | 21 | 160 | OTM |
| 9 C | $0.57 | -37.36% | 196 | 6,793 | OTM |
| 9.5 C | $0.46 | -30.30% | 73 | 78 | OTM |
| 10 C | $0.33 | -49.23% | 108 | 8,626 | OTM |
| 10.5 C | $0.38 | -24.00% | 7 | 40 | OTM |
| 11 C | $0.50 | +66.67% | 162 | 5,088 | OTM |
| 11.5 C | $0.33 | +560.00% | 3 | 8 | OTM |
| 12 C | $0.10 | -28.57% | 41 | 8,364 | OTM |
| 12.5 C | — | — | 0 | 0 | OTM |
| 13 C | $0.10 | +0.00% | 30 | 1,098 | OTM |
| 13.5 C | $0.10 | -66.67% | 41 | 30 | OTM |
| 14 C | $0.05 | +0.00% | 16 | 2,303 | OTM |
| 14.5 C | — | — | 0 | 0 | OTM |
IBRX Profile
immunitybio is a leading registration-stage immuno-oncology and infectious disease company activating both the innate (natural killer cell and macrophage) and adaptive (t cell) immune system. we are developing molecular and product platforms including n-803, aldoxorubicin, and a second-generation adenovirus vector, which are based upon our three key modalities of activating natural killer ('nk') and t cells, tumoricidal macrophages, and memory t cells.